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Protocol
AbstrACt
Introduction Influenza and influenza-like illness (ILI) 
create considerable burden on healthcare resources 
each winter. Children with pre-existing conditions such 
as asthma, diabetes mellitus and cerebral palsy are 
among those at greatest risk of clinical deterioration from 
influenza/ILI. The Antibiotics for at Risk CHildren with 
InfluEnza (ARCHIE) trial aims to determine whether early 
oral treatment with the antibiotic co-amoxiclav reduces the 
likelihood of reconsultation due to clinical deterioration in 
these ‘at risk’ children.
Methods and analysis The ARCHIE trial is a double-
blind, parallel, randomised, placebo-controlled trial. 
‘At risk’ children aged 6 months to 12 years inclusive 
who present within the first 5 days of an ILI episode will 
be randomised to receive a 5-day course of oral co-
amoxiclav 400/57 twice daily or placebo. Randomisation 
will use a non-deterministic minimisation algorithm 
to balance age and seasonal influenza vaccination 
status. To detect respiratory virus infections, a nasal 
swab will be obtained from each participant before 
commencing study medication. To identify carriage of 
potential bacterial respiratory pathogens, we will also 
obtain a throat swab where possible. The primary 
outcome is reconsultation in any healthcare setting due 
to clinical deterioration within 28 days of randomisation. 
We will analyse this outcome using log-binomial 
regression model adjusted for region, age and seasonal 
influenza vaccination status. Secondary outcomes 
include duration of fever, duration of symptoms and 
adverse events. Continuous outcomes will be compared 
using regression analysis (or equivalent non-parametric 
method for non-normal data) adjusting for minimisation 
variables. Binary outcomes will be compared using χ2/
Fisher’s exact test and log-binomial regression.
Ethics The ARCHIE trial has been reviewed and approved 
by the North West-Liverpool East Research Ethics 
Committee, Health Research Authority and Medicines and 
Healthcare Products Regulatory Agency. Our findings will 
be published in peer-reviewed journals and disseminated 
via our study website (www. archiestudy. com) and links 
with relevant charities.
trial registration numbers ISRCTN 70714783; Pre-
results. EudraCT 2013-002822-21; Pre-results.
IntroduCtIon  
background and rationale
Influenza is a viral infection that circulates 
mainly during winter and is a well-recognised 
risk factor for bacterial complications. ‘At risk’ 
children are more prone to becoming seri-
ously unwell from influenza-related compli-
cations than otherwise healthy children.
‘At risk’ children are defined as children 
with underlying medical conditions or risk 
factors associated with an increased likeli-
hood of developing complications from influ-
enza/influenza-like illness (ILI). Based on 
guidance from the UK Department of Health1 
and the US Advisory Committee on Immu-
nization Practices,2 ‘at risk’ groups include 
patients with chronic respiratory, cardiac, 
renal, liver and neurological conditions, as 
well as diabetes mellitus and immunosuppres-
sion. There is also systematic review evidence, 
mainly based on data from children under 2 
years of age, that premature birth (ie, delivery 
before 37 weeks’ gestation) is a risk factor for 
influenza-related complications.3
strengths and limitations of this study
 ► This randomised controlled trial specifically focus-
es on ‘at risk’ children with known risk factors for 
complications from influenza/influenza-like illness 
(ILI), who may potentially benefit most from early 
antibiotic treatment.
 ► The primary outcome (reconsultation due to clinical 
deterioration within 28 days) is clinically relevant 
and has important implications for cost-effective-
ness of early antibiotic treatment.
 ► The study uses a pragmatic case definition of ILI, 
which reflects current clinical practice but does not 
reliably distinguish between influenza infection and 
ILI due to other causes.
2 Wang K, et al. BMJ Open 2018;8:e021144. doi:10.1136/bmjopen-2017-021144
Open Access 
Based on data from Hospital Episode Statistics and 
the Office for National Statistics, 490 000 general practi-
tioner (GP) consultations and 4200 hospitalisations due 
to seasonal influenza occur each year in children aged 14 
years or younger.4 This results in a cost to the National 
Health Service (NHS) of approximately £6.7 million due 
to hospitalisations5 and £18 million due to primary care 
consultations.6 The overall NHS and wider socioeco-
nomic burden is likely to be greater due to additional 
costs incurred by critical care admissions, accident and 
emergency department attendances, clinical interven-
tions (investigations and medications) and parental 
productivity losses (days off work and childcare costs).
Based on recommendations from the Joint Committee 
on Vaccination and Immunisation,7 the UK introduced 
universal seasonal influenza vaccination for all children 
aged 2 and 3 years from 2013/2014, extending to all chil-
dren aged 4 years during the 2014/2015 influenza season. 
In 2017/2018, Public Health England also initiated vacci-
nation of children aged 4–5 years at school rather than in 
primary care and included children in year 4 of school 
(aged 8–9 years) in the childhood influenza vaccination 
programme.8
Vaccine uptake of 55.7% has been observed in areas 
using school delivery models, compared with only 34.7% 
when general practice delivery models are used.9 However, 
vaccination rates in children with ‘at risk’ conditions 
have not improved from around 40% since 2013/2014.10 
Furthermore, effectiveness of the UK 2015/2016 seasonal 
influenza vaccination was only around 58% in children 
aged 2–17 years.11 Evidence for treatment with neuramin-
idase inhibitors in ‘at risk’ children is also weak. Osel-
tamivir has not been demonstrated to provide significant 
benefit in terms of shortening symptom duration12 or 
reducing acute exacerbations13 in children with asthma.
Although there is a substantial evidence base underpin-
ning recommendations that routine antibiotic treatment 
is not indicated for viral respiratory tract infections,14 
there is also preliminary evidence to suggest that early 
antibiotic use may be beneficial in preventing clin-
ical deterioration and complications due to influenza. 
The results of a small, randomised, placebo-controlled 
trial suggest that early treatment with the antibiotic 
sultamicillin in children presenting with influenza/ILI 
significantly reduces the incidence of pneumonia.15 
Additionally, observational data from school-age children 
presenting in primary care with cough and fever found 
that duration of fever was significantly shorter in children 
with laboratory-confirmed influenza who received antibi-
otics (mostly amoxicillin) at an early stage during their 
illness.16
In recognition of the potentially serious clinical and 
socioeconomic consequences of bacterial complications 
of influenza, the UK government stockpiles the antibi-
otic co-amoxiclav for use during influenza epidemics and 
pandemics. Co-amoxiclav is the antibiotic of choice due 
to its coverage of both Streptococcus pneumoniae and Staph-
ylococcus aureus, the most commonly observed bacterial 
coinfections in patients with laboratory-confirmed influ-
enza.17 In particular, S. aureus coinfections are associated 
with worse clinical outcomes in patients with laborato-
ry-confirmed influenza18 and were found in nearly half 
of influenza-related deaths between October 2004 and 
September 2012 among US children from whom at least 
one bacterial pathogen was identified from a normally 
sterile site.19
At the same time, antibiotic prescribing is a major driver 
of antimicrobial resistance,20 which is well recognised as 
an emerging threat to the treatment of serious bacterial 
infections. Data on the potential impact of early co-amox-
iclav use on development and duration of antimicrobial 
resistance are therefore needed to guide future national 
guidance on supply and use of this antibiotic during 
periods of high influenza activity. A clear, evidence-based 
understanding of the benefits versus harms will in turn 
support local antibiotic stewardship programmes and 
better informed, more appropriate decisions about anti-
biotic prescribing and use in the community.21
MEthods And AnAlysIs
objectives
Our primary objective is to determine whether early treat-
ment with co-amoxiclav reduces the likelihood of recon-
sultation due to clinical deterioration in ‘at risk’ children 
with influenza/ILI.
Other objectives are:
 ► To determine whether early treatment with co-amoxi-
clav reduces duration of fever in ‘at risk’ children with 
influenza/ILI.
 ► To determine whether early treatment with co-amoxi-
clav reduces duration of symptoms in ‘at risk’ children 
with influenza/ILI.
 ► To compare further intervention rates in ‘at risk’ chil-
dren with influenza/ILI treated with co-amoxiclav 
versus placebo.
 ► To compare adverse events in ‘at risk’ children 
with influenza/ILI treated with co-amoxiclav versus 
placebo.
 ► To assess the cost, outcomes and cost-effectiveness of 
early treatment with co-amoxiclav in ‘at risk’ children 
with influenza/ILI versus placebo.
 ► To determine the impact on long-term respiratory 
bacterial carriage and antibiotic resistance of early 
treatment with co-amoxiclav versus placebo in ‘at risk’ 
children with influenza/ILI.
study design
The ARCHIE trial is a multicentre, double-blind, 
randomised, placebo-controlled trial. ‘At risk’ children 
(ie, children with known risk factors for influenza-re-
lated complications), who present within the first 5 days 
of an ILI and who are not considered by their clinician 
to require immediate antibiotic treatment or hospital-
isation, will be randomised to receive a 5-day course of 
co-amoxiclav 400/57 mg or a matching placebo. Nasal 
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swabs will be obtained from all participants to detect 
influenza infection. Throat swabs for culture and sensi-
tivity will also be obtained at baseline where possible. The 
primary outcome is reconsultation due to clinical deteri-
oration within 28 days of randomisation.
study participants
We will recruit ‘at risk’ children aged 6 months–12 years 
inclusive who present within the first 5 days of an ILI. 
We will define ILI as the presence of both cough and 
fever, which may be defined as child-reported fever, 
parent-reported fever or temperature >37.8°C (axillary or 
tympanic temperature measurement). This is intended as 
a pragmatic case definition, which can be reliably applied 
across our entire target age range.
Box 1 summarises our definition of ‘at risk’ groups. 
Rather than being an exhaustive list, this definition is 
intended to guide clinicians in identifying which children 
are likely to be at greater risk of influenza-related clinical 
deterioration or complications. Healthcare professionals 
are also advised to use their clinical judgement to iden-
tify ‘at risk’ children. Children with other potential risk 
factors who may be suitable to take part may be discussed 
with a medically qualified member of the research 
team. Children who require immediate antibiotics or 
hospital admission for treatment of an influenza-related 
box 1 ‘At risk’ groups
respiratory
 ► Asthma requiring continuous or repeated use of controller therapy (eg, inhaled steroids, leukotriene receptor antagonists, long-acting beta ago-
nists and systemic steroids).
 ► Admitted to hospital with exacerbation of asthma within the last 12 months.
 ► Admitted to hospital with bronchiolitis or pneumonia within the last 12 months.
 ► Recurrent viral wheeze (three or more episodes within the last 12 months).
 ► Bronchopulmonary dysplasia.
Cardiac
 ► Congenital heart disease being actively managed or monitored by cardiology team.
 ► Chronic heart failure being actively managed or monitored by cardiology team.
neurological
 ► Chronic neurological or neuromuscular disorder that compromises respiratory function (eg, cerebral palsy).
renal
 ► Chronic kidney disease defined as either of the following:
 ► Impaired estimated glomerular filtration rate* (eGFR) measurement within the last 12 months.
 ► Known hereditary or structural kidney abnormality with or without impairment in eGFR.
 ► Nephrotic syndrome.
 ► Kidney transplantation.
liver†
 ► Cirrhosis.
 ► Biliary atresia.
 ► Chronic hepatitis.
Immunodeficiency
 ► Asplenia or splenic dysfunction.
 ► HIV infection.
 ► Undergoing chemotherapy leading to immunosuppression.
 ► Taking systemic steroids at a dose equivalent to prednisolone 20 mg or more per day (any age) or ≥1 mg per kg per day (children under 20 kg).
other
 ► Diabetes mellitus (type 1 or type 2) or other metabolic condition.
 ► Genetic abnormality (eg, Down’s syndrome).
 ► Sickle cell disease.
 ► Malignancy.
 ► Prematurity (born before 37 weeks’ gestation) in children aged 6–23 months.
*Impaired eGFR is defined as an eGFR measurement of 59 mL/min/1.73 m2 or less within the last 12 months before study entry. However, to enter the trial, the 
following two conditions must also be satisfied:
1. eGFR ≥30 mL/min/1.73 m2 based on most recent measurement within the last 12 months.
2. No reason to suspect further deterioration in eGFR at time of study entry.
†Children with mild or moderate liver disease may enter the trial. However, to minimise the risk of serious hepatic complications related to study medica-
tion, children with severe liver disease may not enter the trial. Severe liver disease is defined as hepatic impairment associated with any of the following: 
jaundice, impaired coagulation/increased bleeding risk, bilirubin persistently greater than 50 µmol/L (two measurements within last 12 months).
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complication (based on their clinician’s judgement) will 
not be eligible to take part. Box 2 summarises our full 
inclusion and exclusion criteria. 
recruitment
We will recruit study participants from a range of health-
care settings where ‘at risk’ children from the community 
present with influenza/ILI. Recruiting sites will include 
general practices, walk-in centres and hospitals. Identi-
fication of participants at these sites may be supported 
by the use of participant identification centres. Given the 
seasonal nature with which influenza circulates in the 
community, each recruitment season will commence at 
the beginning of October and continue until the end of 
March the following year or later if influenza continues to 
circulate above seasonal thresholds.
Before each recruitment season, we will ask partici-
pating general practices to perform database searches 
to identify children within our target age range who are 
in ‘at risk’ groups. A medically qualified individual will 
manually screen the results of the database search to 
exclude any children who would not be suitable to invite 
to take part in the study. Recruiting sites may also install 
a study reminder screen prompt, which will appear when 
the electronic medical records of potentially suitable 
children are accessed. Participating hospitals will also 
be asked to identify potential recruits through specialist 
outpatient clinics that manage children with ‘at risk’ 
conditions.
To further raise awareness about the trial and oppor-
tunities for participation, we will provide recruiting sites 
with study promotional materials including posters and 
short information leaflets, which summarise our study 
aims and direct families of potential participants to our 
study website (www. archiestudy. com). We will also liaise 
with recruiting sites to raise awareness via local news 
outlets, social media and charities representing rele-
vant patient groups. Parents who express an interest in 
allowing their child to take part in the study will be able 
to contact the study team or look at the study website to 
find their nearest recruiting site.
During each recruitment season, children who present 
at recruiting sites with influenza/ILI will be screened to 
determine whether they are eligible to take part in the 
trial. Suitably trained healthcare professionals will then 
obtain informed consent for study participation from the 
child’s parent or guardian and complete study enrolment 
and randomisation procedures either at the recruiting 
site or at the child’s home within 24 hours of confirming 
their eligibility for study participation.
Intervention
Participants will be randomised to receive either co-amox-
iclav 400/57 (amoxicillin 400 mg as trihydrate and 
clavulanic acid 57 mg as potassium salt/5 mL when recon-
stituted with water) or a matching placebo, which will 
be taken orally twice daily for 5 days. Study medication 
doses based on age, as well as weight in participants aged 
6–23 months, will be calculated according to the standard 
dosing regimen for co-amoxiclav 400/57 recommended 
by the British National Formulary (BNF; see table 1). 
Study medication will be provided as a dry powder, which 
healthcare professionals will reconstitute with water once 
the participant has been randomised.
Medically qualified individuals will use their clinical 
judgement when advising on study medication doses for 
any children to whom they feel that standard BNF dosing 
recommendations should not apply.
Participants will be allowed to continue their usual 
regular medications and any additional medications for 
their influenza/ILI episode while taking part in the trial.
box 2 study inclusion and exclusion criteria
Inclusion criteria
 ► Aged 6 months–12 years inclusive.
 ► In ‘at risk’ category.
 ► Presenting with influenza-like illness (ie, cough and fever) during 
influenza season.
 ► Presenting within 5 days of symptom onset.
 ► Permanently registered at a general practice in UK.
 ► Parent/guardian able to complete study diary and questionnaires.
Exclusion criteria
The participant may not enter the trial if ANY of the following apply:
 ► Known contraindication to co-amoxiclav.
 ► Child given antibiotics for treatment of an acute infection within the 
last 72 hours.
 ► Child requires immediate antibiotics (clinician’s judgement).
 ► Child requires immediate hospital admission for treatment of an in-
fluenza-related complication (clinician’s judgement).
 ► Child has been observed on hospital ward or ambulatory care unit 
for longer than 24 hours.
 ► Presence of any reason to prevent healthcare professional from ob-
taining nasal swab.
 ► Child with known cystic fibrosis.
 ► Child previously entered into the Antibiotics for at Risk CHildren with 
InfluEnza trial.
 ► Child has been involved in another medicinal trial within the last 
90 days.
Table 1 Study medication dosing regimen
Child’s age Study medication dose
6–23 months
  Under 6 kg Calculate dose according to British 
National Formulary instructions for co-
amoxiclav 400/57. Advise two doses 
daily for 5 days.
  6.0–7.9 kg 1 mL twice daily for 5 days.
  8.0–10.9 kg 1.5 mL twice daily for 5 days.
  11.0–12.9 kg 2 mL twice daily for 5 days.
2–6 years 2.5 mL twice daily for 5 days.
7–12 years 5 mL twice daily for 5 days.
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baseline study procedures
Healthcare professionals will record baseline data from 
study participants on age, sex, comorbidities, household 
smoking status, influenza vaccination status, medications 
given during the current illness episode, duration of fever 
and duration of symptoms. Heart rate and respiratory rate 
will also be measured and recorded at baseline. Other 
baseline characteristics (medical conditions, regular 
medications, vaccinations and acute consultations that 
occurred up to 12 months before randomisation) will be 
extracted from participants’ medical records.
A nasal swab will be obtained from each participant 
at baseline. Nasal swabs will be placed in viral transport 
medium and sent by post to Alder Hey Children’s Hospital 
microbiology department for analysis, where they will be 
analysed by real-time PCR analysis to detect influenza and 
distinguish influenza A, B and A/H1N1 2009 pandemic 
subtypes. Residual medium will be retained for potential 
future detection of other pathogens. Where possible, a 
throat swab will also be obtained from the participant for 
culture and sensitivity. In a subgroup of participants whose 
parents/guardians give additional written informed 
consent, further throat swabs will be collected after 3, 
6 and 12 months. Online supplementary appendix A 
provides further details of the laboratory analyses, which 
will be performed on throat swab samples.
outcomes
The primary outcome is reconsultation due to clinical 
deterioration within 28 days of randomisation. Clinical 
deterioration is defined as any of: worsening symptoms, 
development of new symptoms or development of a 
complication requiring medication or hospitalisation. 
This definition is based on that used by the Genomics 
to combat Resistance against Antibiotics in Communi-
ty-acquired lower respiratory tract infection in Europe 
consortium in order to define reconsultations due to clin-
ical deterioration in patients with lower respiratory tract 
infections.22
Secondary outcomes include duration of fever and 
duration of symptoms from time of randomisation and 
medication prescriptions and/or further investigations, 
adverse events, hospitalisations or deaths, all within 28 
days of randomisation. For the purpose of the economic 
evaluation, outcomes include healthcare resource util-
isation and parental/informal care costs within 28 days 
of randomisation and health-related quality of life as 
measured by the EuroQol health-related quality of life 
youth proxy version (EQ-5D-Y proxy) at baseline and days 
4, 7, 14 and 28.
data collection
Online supplementary appendix B presents a complete 
summary of data collected during the trial. Data obtained 
at the baseline assessment, week 1 and week 2 follow-ups, 
as well as data on safety events, will be entered on paper 
case report forms before being sent to the main trial office 
for entry using OpenClinica open source software (V.3.13; 
Waltham MA, USA), a validated online electronic data 
capture system. All data will be double entered to ensure 
accuracy. Data extracted from the medical notes of chil-
dren recruited from general practices will be directly tran-
scribed into OpenClinica at the child’s general practice. 
The main trial office will contact the general practices of 
children recruited from hospitals or walk-in centres to 
request relevant data from their medical notes, which will 
then be entered by a member of the trial team.
A parent or guardian will be asked to complete and 
return by post a series of four 1-week study diaries on 
behalf of the participant to provide data on doses of 
study medication given to the child, axillary temperature, 
symptoms, adverse events, daily activities and childcare, 
child’s health-related quality of life measured by the 
EQ-5D-Y proxy and health service contacts such as hospi-
talisations and visits to the GP. Healthcare professionals 
will also contact each participant’s parent or guardian 
by telephone 1 week and 2 weeks after randomisation 
to collect data on duration of fever, adverse events and 
adherence to study medication. Primary outcome data 
will be extracted from participants’ medical notes at least 
3 months after randomisation. This is to allow records of 
any hospital admissions or consultations in non-general 
practice settings to be captured in the child’s general 
practice medical record. Data on duration of symptoms 
will be collected from study diaries completed by partici-
pants’ parents/guardians. Data on duration of fever will 
also be collected from study diaries and supplemented 
by follow-up telephone calls with parents/guardians 
1 week and 2 weeks after randomisation. During these 
telephone calls, parents/guardians will be asked whether 
their child’s fever has settled and, if so, when. Data on 
adverse events will also be collected at these telephone 
calls. Data on medication prescriptions, further investiga-
tions, hospitalisations and deaths will be extracted from 
participants’ medical records.
randomisation and blinding
Randomisation will be stratified by region with minimi-
sation for age (6–23 months inclusive versus 2–12 years 
inclusive) and seasonal influenza vaccination status (yes 
or no/do not know). Randomisation is performed using 
Sortition, an online clinical trial randomisation software 
package developed by the Clinical Trials Unit at the 
University of Oxford, Nuffield Department of Primary 
Care Health Sciences. The randomisation system will be 
implemented and managed by the Clinical Trials Unit. 
The randomisation codes will be maintained by a specif-
ically appointed independent custodian. Healthcare 
professionals, the study team, children and parents/
guardians will all be blinded to treatment allocation.
A participant’s treatment allocation will be unblinded 
in the event of a suspected unexpected serious adverse 
reaction. Where there is a perceived need for unblinding, 
the participant’s responsible clinician (ie, the clinician 
treating the participant) will discuss the case with the chief 
investigator or a designated alternative study clinician. If 
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it is agreed that unblinding is required, the chief inves-
tigator or designated study clinician will request that 
the randomisation code is accessed by the independent 
custodian, who will disclose the participant’s treatment 
allocation to his or her responsible clinician.
sample size
A large population-based study using the UK General 
Practice Research Database found that true complications 
occurred in 17.6% of at-risk children aged 1–14 years 
within 30 days of being clinically diagnosed with influ-
enza/ILI.23 Assuming that true complications account 
for 44% of reconsultations due to clinical deterioration,24 
we estimate that 40% (17.6%/44×100) of at-risk children 
with clinical influenza will reconsult with clinical deterio-
ration within 30 days of initial presentation.
We will aim to recruit 650 children into the trial, 
including an inflation factor of 1.041 and allowance 
for 25% loss to follow-up. Our target effective sample 
size is therefore 484 children (242 in each arm), which 
would be sufficient to detect a reduction in reconsulta-
tion due to clinical deterioration from 40% to 26% (a 
35% relative risk reduction) with 90% power and 5% 
two-tailed alpha error. Our inflation factor estimate is 
based on a conservative intracluster correlation estimate 
of 0.0325 and a coefficient of variation of 0.6 (based 
on the value observed in the Diabetes care from Diag-
nosis (DD) trial),26 assuming an average cluster size of 
two patients.27
We acknowledge that recruitment of the above sample 
size is likely to be challenging (see Discussion). However, 
a sample of 280 participants would still be sufficient to 
detect a reduction in reconsultation due to clinical dete-
rioration from 40% to 23% with 80% power and 5% 
two-tailed alpha error, including an inflation factor of 
1.041 and allowance for 5% loss to follow-up. This effect 
size (a 42.5% relative risk reduction) is still conservative 
compared with the effect observed in the aforementioned 
trial conducted by Maeda et al,15 which reported an 85% 
relative risk reduction in incidence of pneumonia in chil-
dren with ILI who were treated with the antibiotic sultam-
icillin (1/42 children) versus placebo (7/43 children). A 
5% loss to follow-up rate should also be achievable given 
that data on reconsultations due to clinical deterioration 
will be extracted from medical notes.
statistical analysis and economic evaluation plan
We will perform an intention-to-treat analysis including 
all randomised participants and use multiple imputa-
tion methods to account for missing data. Specifically, 
the participants will be analysed in the groups to which 
they were allocated. Baseline characteristics will be 
summarised by treatment groups. The results from the 
trial will be presented as comparative summary statistics 
(difference in proportion or means) with 95% CIs. The 
analysis and reporting of results will follow the general 
principles of Consolidated Standards of Reporting Trials 
2010 statement.28
The proportion of children reconsulting due to clinical 
deterioration in the two groups (primary outcome) will 
be compared using a log-binomial regression model with 
adjustment for region, age and seasonal influenza vacci-
nation status. The treatment effect will be reported as a 
relative risk with 95% CI. A p value will also be presented. 
Stability and assumptions of the regression model will be 
explored, and alternative method will be used if any viola-
tion of assumptions occurred.
Analysis of continuous outcomes (eg, duration of 
fever and duration of symptoms) will be compared 
using regression analysis, adjusting for the same factors as 
described above. A non-parametric method will be used 
if assumptions of linear regression are not met. Binary 
outcomes (eg, proportions of children prescribed medi-
cation and/or requiring further investigations, children 
in whom adverse events are reported and children who 
are hospitalised or died within 28 days of randomisation) 
will be compared using χ2/Fisher’s exact test and log-bi-
nomial regression. Sensitivity analyses will be carried out 
to examine the robustness of the results with different 
assumptions about departures from randomisation poli-
cies and handling of missing data.
The incremental costs of administering early treatment 
with co-amoxiclav in ‘at risk’ children with influenza/ILI 
versus placebo will be estimated using the data on health-
care resource use provided by the four 1-week study diaries 
and the medical notes review. We will estimate total costs 
and costs relating to burden on primary care, secondary 
care and parental/informal care. We will extrapolate our 
analysis of resource use and costs to explore the potential 
cost impact of early co-amoxiclav use on a national scale. 
The primary outcome measure for the cost-effectiveness 
analysis will be the EQ-5D-Y proxy. We will estimate and 
report all the costs and consequences in a disaggregated 
format (cost–consequences analysis) as well as analysing 
and reporting the incremental cost and effectiveness in 
terms of cost per quality-adjusted life year of adminis-
tering co-amoxiclav versus placebo alongside a sensitivity 
analysis.
safety and adverse event reporting
We will record all adverse events notified by trial investi-
gators, healthcare professionals or participants as occur-
ring within 28 days of randomisation, whether they are 
related to study medication. However, we will not under-
take formal adverse event reporting for events which 
are known to be common side effects of co-amoxiclav 
(ie, mucocutaneous candidosis, diarrhoea, nausea and 
vomiting)29 unless they result in a serious adverse event 
or are considered by the child’s clinician to be clinically 
severe.
Clinicians will be advised to discontinue a participant’s 
study medication if he or she experiences an adverse drug 
reaction related to the study medication. Parents/guard-
ians of participants whose study medication is discon-
tinued will still be requested to complete their study 
diaries and questionnaires and will still receive telephone 
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follow-up calls unless they choose to withdraw consent for 
these.
The independent Data and Safety Monitoring 
Committee (DSMC) for the trial will be responsible for 
reviewing safety events after each recruitment season. 
The main aims of this review are:
 ► To ensure the safety of each trial participant.
 ► To identify any trends, such as increases in unexpected 
adverse events, and take appropriate action.
 ► To seek additional advice or information from investi-
gators where required.
 ► To evaluate the risk of the trial continuing and take 
appropriate action where necessary.
 ► To act or advise, through the chairperson or other 
consultant, on incidents occurring between meetings 
that require rapid assessment.
The DSMC will also advise on whether the trial should 
be terminated based on its reviews of serious adverse 
events in consultation with the Trial Steering Committee 
and trial sponsor if necessary.
Patient and public involvement
Our patient advisers and patient representatives iden-
tified via the National Institute for Health Research 
(NIHR) Medicines for Children Research Network Clin-
ical Study Groups helped develop and refine our study 
objectives by providing extensive feedback on early draft 
versions of our research plan. To inform the design of our 
trial materials and procedures, we held discussion groups 
with 21 parents of children with ‘at risk’ conditions and 
15 young people in four different locations (Oxford, 
London, Liverpool and Birmingham). These consulta-
tions informed the design of our ‘Archie the penguin’ 
mascot, study information leaflets and study diaries (four 
1-week diaries instead of one diary to be completed over 
4 weeks), as well as selection of the EQ-5D-Y proxy ques-
tionnaire to measure health-related quality of life in trial 
participants. They also prompted us to raise awareness 
about the study before the start of each recruitment 
season, produce a series of short videos on our study 
website to explain the study to parents and guardians 
and initiate set-up of the home visit recruitment model 
in Clinical Research Networks (CRNs) with the resources 
to support this. Patient representatives will also help us 
disseminate our research findings by providing assistance 
with writing plain language summaries and establishing 
links with relevant charities and patient organisations that 
represent parents and children to whom the findings of 
our research will be relevant.
dIsCussIon
Implications of study findings
The findings of the ARCHIE trial will provide important 
evidence to inform clinically appropriate and cost-effec-
tive antibiotic prescribing and use in ‘at risk’ children 
presenting with ILI in community healthcare settings. 
The only randomised placebo-controlled trial conducted 
to date of early antibiotic use in children with ILI15 
excluded children with chronic medical conditions (even 
though these children are at greatest risk of clinical dete-
rioration) and did not evaluate potential implications of 
antibiotic treatment on antimicrobial resistance. There 
are also no studies to date that have examined the cost-ef-
fectiveness, costs and effectiveness of early antibiotic use 
in ‘at risk’ children with influenza/ILI.
The lack of clear, evidence-based guidance in this 
area results in considerable uncertainty and wide varia-
tion in clinical decision making about prescribing anti-
biotics to children with ILI who have known risk factors 
for influenza-related clinical deterioration.30 This may in 
turn result in antibiotics being prescribed unnecessarily, 
leading to emergence of antibiotic-resistant infections,31 
which are associated with worse clinical prognosis, even 
in patients with common respiratory tract infections in 
the community.32
reflection
The ARCHIE trial is now in its fourth and final recruit-
ment season. However, recruitment has proven to be 
more challenging than originally anticipated due to a 
significantly delayed start in recruitment, a limited pool 
of potential recruits and limitations in capacity to recruit 
at participating sites.
We had originally planned to start recruitment in 
October 2014 and continue recruitment over three 
winter seasons (2014/2015, 2015/2016 and 2016/2017). 
However, we were only able to start recruitment on 11 
February 2015 due to delays in obtaining our study medi-
cation. By this time, the peak period of influenza/ILI 
consultation activity in early January 2015 had already 
passed.33
Extension of the UK childhood universal seasonal 
influenza vaccination programme to all children aged 4 
years during winter 2014/2015 and subsequent annual 
extension of that programme to older children may also 
have had an adverse impact on recruitment. Indeed, 
primary care consultation rates for influenza/ILI in 
England peaked at relatively modest levels during winters 
2015/2016 (28.7 per 100 000)34 and 2016/2017 (20.3 per 
100 000)35compared with previous influenza seasons. The 
2016/2017 influenza season was particularly mild, with 
influenza/ILI consultation rates in England remaining 
above the Moving Epidemic Method baseline threshold 
of 14.3 per 100 000 for only 6 weeks.35 However, previous 
research suggests that GPs rarely consider influenza 
infection or ask about vaccination status when assessing 
‘at risk’ children with ILI.30 It is therefore unlikely that 
recruitment would have been significantly compromised 
due to healthcare professionals failing to consider vacci-
nated children as potential recruits.
The highly specific nature of our study eligibility 
criteria also means that recruitment is only possible from 
a limited pool of children with one or more known ‘at 
risk’ conditions (see box 1). Additionally, the healthcare 
professional assessing the child must be satisfied that the 
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child does not require immediate antibiotic treatment. 
This has so far been a major barrier to recruitment, with 
the most common reasons for exclusion at the screening 
stage being receipt of antibiotics within the last 72 hours or 
requirement for immediate antibiotics. This suggests that 
parents and/or healthcare professionals were identifying 
specific reasons to treat these children with antibiotics, 
or erring on the side of caution by initiating antibiotic 
treatment in cases when they were unsure about clinical 
prognosis in the absence of treatment.
Staff at both primary care and hospital ambulatory care 
recruiting sites have reported difficulties with finding 
time to recruit participants alongside other work commit-
ments at a time of increased seasonal health seeking 
activity. Due to the nature of ILI, it is often not possible 
to anticipate when these children will present. Parents 
and children are sometimes unwilling to wait until suit-
ably trained recruiting staff become available. Four-hour 
waiting time targets in hospital emergency departments 
mean that capacity to recruit is particularly limited in 
those settings, especially if there is no alternative space in 
which children can be assessed.
strategies for addressing challenges encountered
To increase our pool of potential recruits, and compen-
sate for our delayed start in recruitment, we have 
increased our total number of recruiting sites as far as 
staff capacity and resources will allow. To support efficient 
training of recruiting staff, we have produced a series of 
training videos on eligibility assessment, baseline clinical 
assessment, nasal and throat swab techniques, randomis-
ation, study questionnaires and diaries, follow-up assess-
ments (including adverse event reporting) and medical 
notes reviews, which can be accessed via our study website. 
Study expansion has also been facilitated by utilisation of 
existing infrastructure within the NIHR CRNs to set up a 
home visit model for recruitment from general practices.
Recruitment via the home visit model started in winter 
2016/2017. This model only requires general practice staff 
to identify potentially eligible children before referring 
them to the study team, who then arrange for a research 
nurse to obtain informed consent and recruit children in 
their homes within 24 hours of initial presentation. This 
is therefore much less burdensome to individual general 
practices than recruiting participants on site.
We have also used CRN infrastructure to identify addi-
tional hospitals as recruiting sites, particularly focusing 
on hospitals with children’s assessment units and direct 
access pathways that allow families of children with 
known ‘at risk’ conditions to bring children directly to 
the children’s assessment unit or ward instead of to the 
emergency department.
Additionally, we made three minor changes to our eligi-
bility criteria in advance of starting recruitment in winter 
2017/2018. Our inclusion criteria now state that children 
who are permanently registered at a general practice in 
the UK (rather than in England only) are potentially 
eligible to participate. This has allowed us to set up the 
ARCHIE trial in Wales, with the support of the Health 
and Care Research Wales Support Centre, which has 
experience of home visit recruitment for primary care 
clinical trials.36 We have also clarified that children who 
have received antibiotics during the last 72 hours will only 
be excluded if these antibiotics were given to treat an 
acute infection. Children on long-term antibiotic prophy-
laxis are therefore still potentially suitable for inclusion 
in the study. Additionally, we have clarified that children 
who are felt to require immediate hospitalisation will only 
be excluded if this is specifically for treatment of an influ-
enza-related complication or for a period of observation 
lasting longer than 24 hours.
Ethics and dissemination
The ARCHIE trial is registered on the International Stan-
dard Randomised Controlled Trials registry (70714783) 
and European Clinical Trials Database (EudraCT: 2013-
002822-21). We have obtained full ethical approval for 
this study from the North West – Liverpool East Research 
Ethics Committee (13/NW/0621), as well as approvals 
from the Health Research Authority and Medicines 
and Healthcare Products Regulatory Agency. All rele-
vant amendments have been assessed and approved by 
Research Ethics Committe/Health Research Authority 
and Medicines and Healthcare products Regulatory 
Authority Local research and development approvals/
confirmation of capacity were received at all recruiting 
sites before recruitment commenced.
The trial will be conducted in accordance with the 
principles of Good Clinical Practice and relevant regu-
lations. Full written informed consent will be obtained 
from a parent or guardian for each study participant. 
Children will also be invited to give written assent if 
appropriate. To ensure that their confidentiality is main-
tained, participants will be identified only by a partici-
pant identification number on all Case Report Forms 
apart from the contact information sheet, consent form 
and assent form (if completed). All documents will 
be stored securely and will only be accessible by trial 
staff and authorised personnel. The study will comply 
with the Data Protection Act, which requires data to be 
anonymised as soon as it is practical to do so.
Our findings will be published in peer-reviewed jour-
nals and disseminated to patients and the public via 
our study website (www. archiestudy. com) and links with 
relevant charities representing children with ‘at risk’ 
conditions.
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